Novartis
Swiss multinational pharmaceutical corporation
Follow Novartis on Notably News to receive short updates to your email — rarely!
| 2024 | Company stabilizes with revenue at $50,317 million and net income at $11,939 million, maintaining a workforce of 75,883 employees |
| 2023 | The Institute for Clinical and Economic Review (ICER) identified Entresto as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence, with its wholesale acquisition cost rising by 7% and resulting in an additional $72 million in costs to U.S. payers. |
| 2023 | Partial financial recovery with net income increasing to $14,854 million, but significant workforce reduction to 76,057 employees |
| October 2023 | Completed the spin-off of Sandoz, finalizing the restructuring process initiated in 2022. |
| 2022 | Net income sharply declines to $6,955 million, with employee count further reducing to 101,703 |
| August 2022 | Novartis announced plans to spin off Sandoz as part of corporate restructuring. |
| 2021 | Significant financial recovery with net income jumping to $24,018 million, the highest in the provided data range |
| 2020 | Novartis continues to see modest revenue growth to $49,898 million, but net income drops to $8,072 million during the COVID-19 pandemic |
| 2020 | Novartis ceased production of methylphenidate (Ritalin). |
| June 2020 | Novartis reached settlements with the US Department of Justice and US Securities and Exchange Commission, paying US$233.9 million to the DOJ and US$112.8 million to the SEC to resolve Foreign Corrupt Practices Act investigations. |
| 2019 | Company experiences a decline in net income to $11,732 million, with employee count reducing to 103,914 |
| August 6 2019 | FDA probe into data manipulation became public, revealing that a senior manager had sold nearly $1 million in stock before the probe's disclosure. |
| June 28 2019 | AveXis voluntarily disclosed to the FDA that previously submitted data for the Zolgensma Biologics License Application was inaccurate. |
| May 2019 | Novartis subsidiary AveXis received FDA approval for Zolgensma, a gene therapy treatment. |
| April 2019 | Novartis spun off its eye-care division Alcon into an independent company. |
| March 26 2019 | FDA approved Mayzent (siponimod), a treatment for secondary progressive multiple sclerosis (SPMS). |
| March 14 2019 | AveXis became aware of data manipulation in the early development of Zolgensma, involving an in vivo murine potency assay. |
| 2018 | Trump's drug pricing plan was released, which included several ideas previously discussed by Novartis and Michael Cohen, effectively protecting pharmaceutical companies from reduced revenues. |
| 2018 | Novartis reports annual revenue of $46,099 million with net income of $12,614 million and 129,924 employees |
| 2018 | Novartis sold its consumer healthcare joint venture vaccines division to GlaxoSmithKline for US$13.0 billion. |
| July 2018 | A US Senate committee report titled 'White House Access for Sale' revealed Novartis's more extensive relationship with Michael Cohen, exposing continued communication between then-CEO Joseph Jimenez and Cohen throughout 2017. |
| March 2018 | GSK announced an agreement to acquire Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). |
| January 2018 | US and Greek authorities began investigating Novartis for alleged bribery of Greek public officials. The manager of Novartis' Greek branch was prohibited from leaving the country. |
| 2017 | Novartis paid $1.2 million to Essential Consultants, a firm owned by Michael Cohen, shortly after Donald Trump's inauguration. The payments were monthly, each just under $100,000, ostensibly to help understand and influence the new administration's approach to drug pricing and regulation. |
| 2015 | End of the alleged bribery period by Novartis involving Greek public officials. |
| 2015 | Novartis completed the sale of its vaccines and diagnostics division, which was integrated into CSL's BioCSL operation and began trading as Seqirus. |
| 2015 | Novartis sold diclofenac (Voltaren) to GlaxoSmithKline in a significant business deal. |
| 2014 | Established a research and development center in Hyderabad, India to offshore clinical development, medical writing, and administrative functions. |
| April 2014 | Novartis divested its consumer health section, creating a $3.5 billion joint venture with GlaxoSmithKline called GSK Consumer Healthcare, in which Novartis retained a 36.5% stake. |
| 2013 | Teva introduced a generic version of Tobi (tobramycin) in the United States. |
| 2013 | Novartis announced plans to consider selling its vaccines and diagnostics division. |
| 2012 | Focalin XR became available. |
| January 2012 | Tasigna (nilotinib) received NICE formulary approval for chronic myelogenous leukemia first-line treatment. |
| 2010 | Novartis offered US$39.3 billion to fully acquire Alcon, the world's largest eye-care company, after previously buying a 25 percent stake in 2008. The total cost for Alcon amounted to $60 billion. |
This contents of the box above is based on material from the Wikipedia article Novartis, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.